Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.
Status:
Recruiting
Trial end date:
2023-02-03
Target enrollment:
Participant gender:
Summary
This study is an open, multicenter, prospective phase I dose escalation clinical trial
followed by an expansion cohort. The aim of this study is to asses the Recommended Phase 2
Dose (R2PD) and the safety profile, among other efficacy, in FGFR1/2/3 positive, hormone
receptor-positive breast cancer (HRPBC) patients with metastatic disease after progression to
the combination of an aromatase inhibitor plus palbociclib, abemaciclib or ribociclib,
according RECIST 1.1 criteria.
Phase:
Phase 1
Details
Lead Sponsor:
Fundacion CRIS de Investigación para Vencer el Cáncer